Isolation of experimental anti-AIDS glycerophospholipids by micro-preparative reversed-phase high-performance liquid chromatography

• Published in: Journal of chromatography Vol. 590; no. 1; p. 153
• Main Authors: Amari, J V, Brown, P R, Pivarnik, P E, Sehgal, R K, Turcotte, J G
• Format: Journal Article
• Language: English
• Published: Netherlands 24.01.1992
• Subjects: Acquired Immunodeficiency Syndrome - drug therapy; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Dideoxynucleotides; Phosphatidic Acids - isolation & purification; Phosphatidic Acids - therapeutic use; Spectrophotometry, Ultraviolet; Zalcitabine - analogs & derivatives; Zalcitabine - isolation & purification; Zalcitabine - therapeutic use; Zidovudine - analogs & derivatives; Zidovudine - isolation & purification; Zidovudine - therapeutic use

The experimental anti-AIDS glycerophosphatidic acid: nucleoside (sn-1/sn-2 diacylglycerol:dideoxynucleotide) drugs 3'-azido-3'-deoxythymidine monophosphate diglyceride (AZT-MP-DG) and 2',3'-dideoxycytidine monophosphate diglyceride (ddC-MP-DG) were isolated and purified by reversed-phase high-performance liquid chromatography (HPLC). The chromatographic separation was based on the glycerophospholipid moiety of the drugs and detection of the nucleoside component. The separations were optimized on method development columns packed with the stationary phase to be used in the micro-preparative column and monitored by a UV detector. Fractions were collected and analyzed for purity by analytical-scale HPLC and by thin-layer chromatography (TLC). The purity of the recovered drugs based on UV and light-scattering detection and on TLC was greater than 99%. The purified compounds were isolated for studies on structure confirmation, physical, biophysical and formulation properties and anti-HIV efficacy in culture.